Life Science Analytics, March 2008, Pages: 190
"Autoimmune And InflammationInflammation " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company
Avance, March 2009, Pages: 38
The report "Success Rates in Biotech - Going The Wrong Way" summarises our review of 211 public biotech companies comprising over 1,500 drug development projects. We have studied the clinical
Life Science Analytics, March 2008, Pages: 79
"Autoimmune And InflammationAutoimmune Diseases " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company
Business Insights, Jan 2010, Pages: 106
of these products must be approached carefully. This report uses a mixture of case studies and data from secondary sources to elucidate the key issues in the development of orphan drugs and ways to navigate them
Life Science Analytics, March 2008, Pages: 164
"Autoimmune And Inflammation Transplant Rejection or Transplantation " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy
Life Science Analytics, March 2008, Pages: 191
"Autoimmune And Inflammation Allergy" contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage
Life Science Analytics, March 2008, Pages: 79
"Autoimmune And Inflammation Lupus " contains detailed information on the current drugpipeline. This report provides insight into the pipeline status of allergy drugs by company and by stage
La Merie, Jan 2009, Pages: 21
processes including inflammation and autoimmunity.
The report includes a compilation of current active projects in research and development of subtype-selective and multi-PKC inhibitors as well as of PKC
Global Markets Direct, Nov 2011, Pages: 48
SEEK – Product Pipeline Review – H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Seek - Product Pipeline Review - H2 2011” provides data on the Seek’s research and development
GlobalData, Dec 2011, Pages: 79
Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD
Datamonitor, July 2010, Pages: 245
assessing induction and maintenance treatment in separate studies of new drugs will play a significant role in drug labeling, particularly for the European Medicines Agency.
Two key late-stage pipelinedrugs
Global Markets Direct, Nov 2011, Pages: 44
Description
Mechanism of Action
R&D Progress
Ilaris - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Inflammation And Autoimmune Diseases - Drug Profile
Fuji-Keizai USA, Inc., April 2003, Pages: 162
of companies and their products among the therapeutic classes of emerging biopharmaceutical companies.
AUTOIMMUNE/INFLAMMATION MARKET SEGMENT
- Figure 3. Distribution of lead drug candidates by stage
GlobalData, Oct 2011, Pages: 14
Cytokine PharmaSciences, Inc. - Product Pipeline Analysis Summary Cytokine PharmaSciences, Inc. (CPSI) is engaged in the development and manufacture of drug delivery products. The company's focus
Espicom Business Intelligence Ltd, April 2009, Pages: 100
of products in the following therapeutic areas: Cardiovascular and Respiratory; Neurology; Immunology and Inflammation; and Gastrointestinal and Metabolism.
Market conditions in Japan are becoming increasingly
Frost & Sullivan, Oct 2003
with Autoimmune/Inflammation among Top 5 of Its Segment-wise Payouts (Global), 1985-2002
Drug Discovery Contract Research Markets: Big Pharma with Broad-based screening among Top 5 of Its Segment-wise Payouts
Datamonitor, April 2009, Pages: 150
recent involvement in the pipeline. Datamonitor believes a drug for celiac disease is up to 5 years away and this untapped gastrointestinal indication has the potential to become a lucrative market.
Scope
iCD Research, Dec 2011, Pages: 33
antibody-based drugs and products for the treatment of cancer, inflammation, and autoimmune diseases. The company has a pipeline of promising drug candidates, a clinically validated technology platform
